Treatment continuity of MEK inhibitors and tumor trajectories after discontinuation in NF1 associated plexiform neurofibromas
Abstract Background: MEK inhibitors have improved the management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs), but the relationship between treatment continuity and post-discontinuation tumor behavior in routine practice remains unclear. Methods: We retrospectively analyzed 40 patients with NF1-associated PNs treated with selumetinib or luvometinib at a tertiary referral center. Patients were classified as discontinuation or no discontinuation according to treatment continuity during follow-up. Outcomes were assessed using a harmonized T0/T1/T2 framework. Pain was evaluated using the Numeric Rating Scale (NRS), and longitudinal tumor change was measured in the same predefined target lesion. Results: Nineteen patients discontinued treatment and 21 remained on treatment. Compared with the no-discontinuation group, the discontinuation group showed less favorable tumor trajectories, with smaller tumor shrinkage at T1 (P = 0.0107), tumor regrowth at T2 relative to baseline (P < 0.0001), and greater tumor rebound (P < 0.0001). In paired analyses within the discontinuation group, median tumor volume changed from − 5.0% at T1 to 5.0% at T2 (P = 0.0003). Pain outcomes were more heterogeneous, with no significant between-group difference in pain rebound. Among patients who discontinued treatment, cost-related interruption was the most frequent documented reason (10/19, 52.6%). Conclusions: In this real-world NF1-PN cohort, treatment discontinuation was common and was associated with less favorable tumor trajectories over time. The clearest post-discontinuation signal was observed in tumor rebound, whereas symptom changes were more heterogeneous. Cost-related interruption was the most frequent documented reason for discontinuation, suggesting that financial burden may represent an important practical barrier to sustained MEK inhibitor therapy.
Authors
- Zhenlei Liu (ORCID: https://orcid.org/0000-0003-0827-4420)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-5305-8543)
- Hao Wu
Institutions
- Capital Medical University (CN)
- Xuan Wu Hospital of the Capital Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1007/s12672-026-06300-6
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00